Treatment of Hepatitis c by Using Direct-acting Antiviral

Tanta University

Status: Unknown

Conditions: Hepatitis C

Treatments: Drug: Direct Acting Antivirals

Study type: Observational

Funder types: Other

Identifiers

NCT05372874

Hepatitis C

Details and patient eligibility

About

Patients with hepatitis c showed increased level of oxidative stress. Increased level of serum lipid peroxidation leads to the production of toxic mediators as malondialdehyde (MDA) which lead to disease progression. Chronic stress shunt tryptophan which is essential amino acid toward kynurenic pathway leading to lower level of serotonin and melatonin level. Currently, direct-acting antivirals (DAAs) show well-established efficacy against hepatitis C virus (HCV).

Enrollment: 50 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• chronic hepatitis C patients had no other cause of liver disease

Exclusion criteria

• Patients with hepatitis B virus (HBV).
• Patients with acute hepatitis.
• Patients with renal insufficiency.
• Patients with Hepatocellular carcinoma (HCC) or other types of malignancy.
• Patients on current use of melatonin.
• Patients using of any of medications that have interaction with melatonin.
• Patients work in night shifts.
• Patients are consuming a lot of caffeine or heavy smokers.

Trial design

50 participants in 3 patient groups

Healthy voluntaries control group (Group 1)

sofosbuvir/daclatasvir treated group (group 2)

Treatment:

Drug: Direct Acting Antivirals

sofosbuvir /daclatasvir/ ribavirin treated group (group 3)

Treatment:

Drug: Direct Acting Antivirals